Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Paclitaxel, and Ramucirumab in Advanced Non-Squamous NSCLC
NCT04332367Phase 2
Key facts
- Status
- Recruiting
- Start
- Aug 2020
- Primary completion
- Sep 2026
- Countries
- 1
- Sponsor
- Abramson Cancer Center
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, Paclitaxel Micelles for Injection and ramucirumab in non-small cell lung cancer (NSCLC), sponsored by Abramson Cancer Center. Primary endpoint: Overall Response Rate at 3 years. Started Aug 2020; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Carboplatin, Taxane And Ramucirumab
Carboplatin AUC 5 IV every 3 wks, Paclitaxel 80 mg/m2 IV days 1 and 8 every 3 weeks, and Ramucirumab 10 mg/kg IV every 3 weeks
03
Who it enrols
Adults with advanced non-squamous NSCLC who progressed after maintenance pemetrexed and/or pembrolizumab, with ECOG PS 0-1, and no targetable driver mutations or untreated brain metastases.
04
Endpoints
Primary
Overall Response Rate
Secondary
Progression-Free Survival
Overall Survival
Number of Grade >= 3 Adverse Events
Beyond the preview
Go deeper on NCT04332367.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04332367.